This multimillion-dollar award reflects an integration of federal funding and institutional contributions from both the University of Cincinnati (UC) and Cincinnati Children’s, collectively amassed to surpass $65 million in total investment towards the CCTST. Since its establishment in 2005, the CCTST has been a cornerstone for fostering translational research within UC’s Academic Health Center, reflecting nearly two decades of commitment to accelerating scientific breakthroughs that revolutionize patient care.

Translational science endeavors to bridge fundamental research and patient-oriented outcomes, transforming biomedical insights into efficacious diagnostics, therapeutics, and preventive strategies. Over the past years, the CCTST has supported more than 8,000 investigators and trainees, fostering an environment rich in interdisciplinary collaboration and cutting-edge innovation. This extensive network accelerates the journey from bench to bedside, ensuring that scientific advancements translate swiftly and effectively into improved health outcomes.

The recent funding award is more than a financial boost—it is a reaffirmation of the synergistic partnership between two of the region’s foremost medical institutions, the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital. Gregory C. Postel, MD, dean of the College of Medicine and UC’s executive vice president for health affairs, highlights the award’s significance, noting that it will enhance the center’s capacity to mobilize clinical and translational research, deepen community engagement, and address pressing public health challenges with innovative precision.

A key evolution envisioned in this funding cycle is the transformation of the CCTST into an integrated Clinical and Translational Learning System (CTLS). This system aims to streamline the discovery-to-implementation pipeline by fostering an ecosystem where researchers, clinicians, trainees, and community stakeholders collaborate seamlessly. The CTLS framework will harness data analytics, translational methodologies, and educational initiatives to shorten the lag between scientific discovery and clinical application.

The impact of this award extends beyond infrastructural support. Per Dr. Tina Cheng, chief medical officer and chair of pediatrics at Cincinnati Children’s, the investment underpins the critical infrastructure that sustains high-caliber medical research. This infrastructure facilitates rigorous study designs, robust biostatistical analysis, and effective community-based partnership models—all essential to rendering research findings actionable, lessons that lead to improved health for both pediatric and adult populations.

Strategic priorities for the next seven years include refining research methodologies, enhancing collaborative networks among scientists and community entities, and ensuring rapid dissemination and implementation of innovations. The program’s expansion will entail advanced training curricula for emerging researchers, embedding precision health approaches designed to address complex public health issues, as well as robust development of safe, efficient, and patient-centered research systems.

The CCTST’s unique infrastructure offers an unparalleled platform for interdisciplinary research, augmenting translational efforts across diverse medical disciplines. Brett Kissela, MD, executive vice dean at the UC College of Medicine, emphasizes the center’s national leadership role and its capacity to convert foundational discoveries into tangible therapies and interventions with measurable clinical benefits. This leadership is critical to maintaining the momentum of biomedical innovation in a highly competitive research environment.

Guided by experienced co-directors including Jareen Meinzen-Derr, PhD, Achala Vagal, MD, and Jeffrey Strawn, MD, the center harnesses a broad coalition of over 40 faculty and staff from both UC and Cincinnati Children’s. Their collective expertise spans biostatistics, radiology, psychiatry, and translational science administration, ensuring a comprehensive, multidisciplinary approach to research facilitation and grant stewardship.

The co-directors articulate a vision centered on delivering an integrated clinical and translational learning system that empowers all stakeholders—from scientists to community members—to contribute to a dynamic knowledge exchange. This vision fosters resilience in translational pipelines and ensures that scientific advancements truly result in improved lives across demographic boundaries.

In an era where public health concerns demand swift and effective responses, the CCTST stands out as a beacon of innovation and collaboration. Its renewed funding will accelerate vital translational research that targets critical health challenges, embodying the NIH’s mission to make science matter through improved health outcomes and reduced health disparities.

The CCTST’s model of combining cutting-edge research technologies, comprehensive training programs, and extensive community engagement programs sets a standard in biomedical research infrastructure nationwide. Deploying the Clinical and Translational Learning System will reinforce the center’s ability to deliver personalized, precision health interventions powered by data-driven insights, thereby catalyzing a new epoch of medical breakthroughs.

With this renewed seven-year commitment, the University of Cincinnati and Cincinnati Children’s are positioned to lead the next wave of translational science innovation. Their integrated approach promises significant improvements in clinical trial design, participant recruitment, and data integration across research domains — all crucial to expediting the delivery of novel therapeutic solutions to patients in urgent need.

Subject of Research: Clinical and Translational Science, Biomedical Research Infrastructure, Precision Health, Research Training, Public Health Innovation

Article Title: University of Cincinnati and Cincinnati Children’s Secure $37.2 Million NIH Award to Propel Clinical and Translational Science into a New Era

News Publication Date: Not provided

Web References: Not provided

References: Not provided

Image Credits: Not provided

Keywords: Biomedical research funding, Human health

Extracellular vesicles, which include exosomes and microvesicles, have rapidly ascended from obscurity to a central focus in cell biology and medicine. Once dismissed as mere cellular debris, EVs are now recognized as critical carriers of molecular information. They transport a diverse cargo—encompassing nucleic acids, proteins, lipids, and even mitochondrial components—across cellular boundaries, facilitating intercellular signaling and remote modulation of physiological functions. These vesicles act as sophisticated biological messengers, dynamically coordinating processes ranging from immune responses to metabolic regulation and neural communication.

The theme guiding this next congress, “Bridging Two Frontiers: Mitochondria & Microbiota,” reflects an ambitious vision to unify insights into two of the most compelling biological realms. Mitochondria, the cellular powerhouses, are instrumental not only in bioenergetics but also in signaling pathways that regulate cell fate and function. Meanwhile, the microbiota—complex communities of microorganisms residing in the human body—play pivotal roles in systemic health, influencing everything from inflammation to brain function. Extracellular vesicles serve as a molecular bridge linking these domains, facilitating bidirectional communication that shapes health and disease.

Mitochondrial biology and EV research converge particularly in understanding how vesicles can carry mitochondrial DNA, proteins, and even organelle fragments. This mitochondrial cargo transported by EVs can profoundly influence recipient cells by altering their energy metabolism or stress responses. Such vesicle-mediated mitochondrial transfer has significant implications for conditions characterized by mitochondrial dysfunction, including neurodegenerative diseases, metabolic syndromes, and aging. By elucidating these pathways, researchers hope to harness EVs as both diagnostic biomarkers and vectors for targeted therapies.

Simultaneously, the microbiome-derived extracellular vesicles are gaining attention for their role as mediators of host-microbe interactions. Bacterial EVs can modulate immune responses, gut-liver communication, and even influence the gut-brain axis, impacting neurological health. These microbial vesicles carry unique molecular signatures capable of triggering inflammatory cascades or promoting homeostasis, thus representing a critical axis of interkingdom communication. Understanding this crosstalk opens new avenues for microbiota-targeted interventions in chronic diseases and immune disorders.

Dr. Marvin Edeas, President of the Mitochondria & Microbiota Task Force and Chairman of the Scientific Committee, eloquently summarizes the transformative potential of EVs. He likens them to “molecular SMS messages,” underscoring their role in transmitting biological information between distant cells and organs. This analogy captures the intricate and dynamic nature of EV-mediated communication networks that orchestrate immunity, metabolism, brain function, and aging. Despite rapid progress, many fundamental questions remain about the evolutionary origins, selection, and regulatory mechanisms governing EV cargo packaging and release.

Decoding the molecular “language” of EVs stands as a paramount challenge with far-reaching implications. Unlocking the mechanisms by which cells control EV content and targeting could revolutionize precision medicine. EVs are poised to redefine diagnostics as non-invasive biomarkers capable of revealing disease states at early stages. Moreover, by engineering EVs to deliver therapeutic molecules selectively, researchers envision novel treatments that minimize off-target effects and enhance efficacy. This frontier exemplifies the convergence of basic science, biotechnology, and clinical innovation.

The congress program has been meticulously designed to foster deep scientific engagement with sessions spanning fundamental biology to translational research. Participants will benefit from keynote lectures delivered by eminent scientists, thematic discussions on bioenergetics, microbiota-host interactions, and clinical applications. The inclusion of sessions focused on oxidative stress, retinal and metabolic diseases, and inflammatory pathways underscores the broad relevance of EV science across biomedical disciplines. Additionally, attention to regulatory and commercial aspects aims to catalyze the translation of EV technologies from bench to bedside.

Of particular note is the dedicated Start-up / Industry & Investor Showcase embedded within the program. This innovative forum will present emerging biotech companies pioneering EV-based therapeutics and diagnostics. By facilitating dialogue between academia, industry, and investors, the congress aims to accelerate technology development and commercialization, thereby amplifying the impact of extracellular vesicle research on healthcare. Such integration highlights the strategic importance of EVs as a platform technology with vast potential across multiple sectors.

Attendees can expect rich interdisciplinary interactions empowered by the congress’s collaborative ethos. The integration of mitochondrial medicine and microbiota research within the EV framework represents a paradigm shift toward understanding human health as a networked system. The event will also address standardization challenges in EV isolation, characterization, and clinical implementation, critical for advancing the field’s reproducibility and regulatory acceptance. Collective efforts in these domains will underpin the future of EV-based diagnostics and therapeutics.

The location of the congress, Valencia, Spain, offers an inspiring setting for this international scientific exchange. Known for its vibrant research community and innovative biotech landscape, Valencia provides an ideal backdrop for fostering collaborations that will shape the next decade of extracellular vesicle science. The congress is open to researchers, clinicians, industry leaders, media, and institutional stakeholders, creating a dynamic environment for knowledge dissemination, partnership formation, and strategic networking.

Media representatives seeking in-depth coverage or interviews with key thought leaders are encouraged to connect with the organizers for exclusive access. The conference also serves as a platform to promote awareness of EV science’s transformative implications for medicine, lifestyle, and society at large. As extracellular vesicles emerge from obscurity to center stage, the event will spotlight their potential to revolutionize our understanding of biology and unlock novel therapeutic frontiers.

In summary, the Second World Congress on Targeting Extracellular Vesicles is poised to be a landmark event, uniting diverse disciplines around one of the most exciting scientific developments of our time. As EV research continues to unravel the complexities of intercellular communication and bioactive cargo transfer, the knowledge generated here will pave the way toward innovative diagnostics and therapies. This congress represents a critical nexus where mitochondrial biology, microbiota science, and vesicle technology converge to shape the medicine of tomorrow.

Subject of Research: Extracellular Vesicles in Mitochondrial Biology and Microbiota Communication
Article Title: Targeting Extracellular Vesicles 2025: Bridging Mitochondria and Microbiota to Revolutionize Medicine
News Publication Date: June 2024
Web References: https://targeting-exosomes.com
Image Credits: @Targeting Extracellular Vesicles 2025
Keywords: Exosomes, Microbiota, Gut Microbiota, Organelles, Vesicles

This research initiative is one of the first to receive funding from the newly established RAISe+ Scheme, which stands for Research, Academic and Industry Sectors One-plus Scheme. Launched in October 2023, this expansive government program is backed by a $10 billion funding allocation aimed at accelerating the transformation of research and development outcomes from initial stages to full-scale implementation. It is designed to facilitate robust collaboration among key stakeholders, including government bodies, industries, universities, and the broader research community. Projects under this scheme can secure matching funds of up to HK$100 million, underscoring the significant investment in the future of scientific research in Hong Kong.

The research venture, titled “Microfluidics-Based Detection Platform for Circulating Tumor Cells and Its Applications in Cancer Early Screening and Disease Monitoring,” is under the astute leadership of Professor Michael Yang Mengsu, who serves as both the Senior Vice-President for Innovation and Enterprise and the Yeung Kin Man Chair Professor of Biomedical Sciences at CityUHK. Under his guidance, the project aspires to create a next-generation CTC detection platform characterized by unparalleled sensitivity and specificity, aimed at meeting critical clinical requirements in the domains of early cancer screening and diagnostic evaluation.

Circulating tumor cells are particularly intriguing in the realm of cancer diagnostics, as they are detachments from a primary tumor that enter the bloodstream. Professor Yang elaborates on their significance, stating that CTCs encapsulate vital molecular genetic and cellular information pertaining to the primary tumor, thereby providing a unique window into the cancer’s biological behavior. He emphasizes the importance of precision diagnosis and comprehensive multi-omics analysis of these cells for effective cancer screening, ongoing disease monitoring, and the development of next-generation cell therapies and mRNA vaccines targeting specific tumor antigens. This intricate interplay of molecular data is pivotal for advancing personalized cancer treatment, tailoring therapeutic approaches that are closely aligned with the individual patient’s tumor profile.

The research team at CityUHK has demonstrated a consistent focus on innovation through the development of biochips and nanotechnology tailored for molecular diagnostics and therapeutics. Their accumulated expertise has led to the transformation of numerous academic research findings into clinically viable solutions, culminating in the establishment of multiple biotech companies. These efforts have leveraged CityUHK’s patented technologies, bringing measurable benefits to millions of patients, and accentuating the university’s commitment to societal impact through scientific inquiry. In a testament to his significant contributions, Professor Yang was recently elected as a Fellow of the National Academy of Inventors in 2024, recognizing his extensive achievements in innovation, economic development, and societal welfare.

The intrinsic value of circulating tumor cell testing lies in its multifaceted applications across tumor detection and treatment frameworks. Despite the promise shown by CTCs, ongoing limitations in current detection methodologies have hampered the full realization of their potential. Professor Yang and his colleagues have established a biotech enterprise, Cellomics, dedicated to commercializing technologies developed at CityUHK. Their pioneering products have already found a foothold in more than 50 hospitals throughout Mainland China, demonstrating the practical impact of their research on clinical practices.

The RAISe+ funding marks a significant milestone in the ongoing collaboration between government agencies, industry players, and academic institutions. With this financial backing, Professor Yang’s team is poised to embark on the design and development of an innovative platform that synergizes microfluidic chip technology with specialized immune-microparticle isolation techniques. This innovative approach is aimed at facilitating efficient and sensitive screening of circulating tumor cells based on their unique physical and biological properties.

The inherent challenges associated with CTC detection—including the rarity of these cells in blood samples and the complexity of their interactions with the blood matrix—require not only innovative technologies for enrichment and characterization but also the establishment of robust CTC-based cultures for comprehensive analysis. These advancements hold the potential to lay the groundwork for groundbreaking applications, such as personalized cancer vaccines and cell-based therapies, ushering in a new era of customized treatment options for patients battling cancer.

The envisioned project is multifaceted and aims for commercialization within the next two years. An integrated system will be developed, encompassing not only a state-of-the-art automated CTC sorting instrument but also cell staining devices and imaging systems, along with reagent kits for CTC profiling. Together, these components will facilitate the counting, classification, and downstream detection of proteins and genetic material associated with CTCs. Such advancements will empower early detection strategies, enhance diagnostic accuracy, and ultimately improve treatment selection and efficacy—all of which are critical for advancing precision medicine in oncology.

Professor Yang asserts the project’s dedication to establishing a commercially viable CTC detection system tailored specifically for cancer screening and monitoring. With an ambitious aim to increase early detection rates and enhance treatment effectiveness, the innovative technology being developed stands to significantly improve the quality of life for countless cancer patients by delivering timely and precise care that is fundamentally focused on individual patient needs.

As this groundbreaking project unfolds, it embodies the spirit of collaboration and innovation that is critical in the fight against cancer. Through the pioneering work at CityUHK, researchers are not only contributing to the scientific understanding of cancer biology but are also translating knowledge into practical applications that hold the promise of changing lives. With ongoing advancements in bioengineering and molecular diagnostics, the quest for a more effective and personalized approach to cancer care continues, offering hope for a future where cancer detection and treatment are not only more efficient but also profoundly humane.

Subject of Research: Early detection of cancer through circulating tumor cells
Article Title: Innovative Advances in Cancer Detection: CityUHK’s Cutting-Edge Technology Platform
News Publication Date: [Please insert date]
Web References: [Please insert URL if available]
References: [Please insert references if available]
Image Credits: City University of Hong Kong

Keywords: Circulating tumor cells, Cancer diagnostics, Precision medicine, City University of Hong Kong, RAISe+ Scheme, Microfluidics, Professor Michael Yang Mengsu, Personalized cancer treatment, Biotech innovation.